SGHT · Sight Sciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.70M | - | $19.91M | $19.56M | $17.51M | - | $20.16M | $21.37M | $19.27M | - |
| Cost of Revenue | $2.72M | - | $2.71M | $2.98M | $2.41M | - | $3.25M | $3.02M | $2.79M | - |
| Gross Profit | $16.98M | - | $17.20M | $16.59M | $15.09M | - | $16.91M | $18.34M | $16.47M | - |
| R&D | $2.55M | - | $3.35M | $4.39M | $4.43M | - | $4.75M | $4.32M | $4.64M | - |
| SG&A | $26.84M | - | $21.75M | $23.87M | $24.52M | - | $23.39M | $26.68M | $26.56M | - |
| Total Operating Expenses | $29.39M | - | $25.10M | $28.25M | $28.95M | - | $28.14M | $31.00M | $31.20M | - |
| D&A | $103.0K | - | $100.0K | $100.0K | $149.0K | - | $100.0K | $100.0K | $192.0K | - |
| Operating Income | ($12.41M) | - | ($7.91M) | ($11.67M) | ($13.86M) | - | ($11.23M) | ($12.65M) | ($14.72M) | - |
| Interest Expense | $1.27M | - | $1.31M | $1.28M | $1.26M | - | $1.15M | $1.15M | $1.20M | - |
| Income Tax | $11.0K | - | ($79.0K) | $40.0K | $41.0K | - | $166.0K | $15.0K | $17.0K | - |
| Net Income | ($12.98M) | - | ($8.17M) | ($11.94M) | ($14.15M) | - | ($11.07M) | ($12.33M) | ($16.27M) | - |
| EPS - Basic | ($0.24) | - | ($0.16) | ($0.23) | ($0.28) | - | ($0.22) | ($0.25) | ($0.33) | - |
| EPS - Diluted | ($0.24) | - | ($0.16) | ($0.23) | ($0.28) | - | ($0.22) | ($0.25) | ($0.33) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $84.96M | $91.97M | $92.37M | $101.50M | $108.77M | $120.36M | $118.56M | $118.18M | $127.28M | $138.13M |
| Accounts Receivable | $10.60M | $9.74M | $9.74M | $9.61M | $9.42M | $10.79M | $12.93M | $19.92M | $15.64M | $14.29M |
| Inventory | $7.01M | $7.77M | $7.98M | $6.21M | $5.80M | $6.33M | $6.09M | $6.78M | $6.87M | $7.85M |
| Accounts Payable | $1.49M | $1.34M | $1.74M | $2.08M | $2.77M | $1.69M | $1.30M | $1.92M | $1.67M | $1.73M |
| Current Assets | $106.51M | $112.73M | $113.59M | $119.43M | $126.91M | $139.77M | $140.47M | $146.33M | $152.09M | $162.87M |
| Total Assets | $109.70M | $115.30M | $116.26M | $121.97M | $129.68M | $142.84M | $143.60M | $149.72M | $155.56M | $166.65M |
| Current Liabilities | $18.16M | $11.03M | $11.83M | $11.94M | $12.12M | $15.47M | $13.80M | $13.29M | $11.69M | $12.25M |
| Long-term Debt | $36.74M | $40.30M | $40.07M | $39.82M | $39.58M | $39.36M | $34.15M | $33.77M | $33.70M | $31.71M |
| Total Liabilities | $55.80M | $51.36M | $51.97M | $51.96M | $52.05M | $55.32M | $48.64M | $48.08M | $46.35M | $46.44M |
| Stockholders' Equity | $53.90M | $63.94M | $64.29M | $70.01M | $77.63M | $87.52M | $94.96M | $101.64M | $109.21M | $120.22M |
| Retained Earnings | ($397.70M) | ($384.72M) | ($380.56M) | ($372.39M) | ($360.45M) | ($346.30M) | ($334.45M) | ($323.38M) | ($311.06M) | ($294.79M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($7.03M) | - | - | - | ($11.61M) | - | - | - | ($9.79M) | - |
| Investing Cash Flow | ($60.0K) | - | - | - | $0 | - | - | - | ($117.0K) | - |
| Financing Cash Flow | $88.0K | - | - | - | $16.0K | - | - | - | ($942.0K) | - |
| CapEx | $60.0K | - | - | - | $0 | - | - | - | $117.0K | - |
| Free Cash Flow | ($7.09M) | - | - | - | ($11.61M) | - | - | - | ($9.90M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 86.2% | - | 86.4% | 84.8% | 86.2% | - | 83.9% | 85.8% | 85.5% | - |
| Operating margin | -63.0% | - | -39.7% | -59.6% | -79.2% | - | -55.7% | -59.2% | -76.4% | - |
| EBITDA margin | -62.5% | - | -39.2% | -59.1% | -78.3% | - | -55.2% | -58.7% | -75.4% | - |
| Net margin | -65.9% | - | -41.0% | -61.0% | -80.8% | - | -54.9% | -57.7% | -84.4% | - |
| Free cash flow margin | -36.0% | - | - | - | -66.3% | - | - | - | -51.4% | - |
| FCF / Net income | 0.55 | - | - | - | 0.82 | - | - | - | 0.61 | - |
| R&D / Revenue | 12.9% | - | 16.8% | 22.4% | 25.3% | - | 23.5% | 20.2% | 24.1% | - |
| SG&A / Revenue | 136.3% | - | 109.3% | 122.0% | 140.1% | - | 116.0% | 124.8% | 137.9% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -11.8% | - | -7.0% | -9.8% | -10.9% | - | -7.7% | -8.2% | -10.5% | - |
| Return on equity | -24.1% | - | -12.7% | -17.1% | -18.2% | - | -11.7% | -12.1% | -14.9% | - |
| Return on invested capital | -10.8% | - | -6.0% | -8.4% | -9.3% | - | -6.9% | -7.4% | -8.1% | - |
| Liquidity | ||||||||||
| Current ratio | 5.86 | 10.22 | 9.60 | 10.01 | 10.47 | 9.04 | 10.18 | 11.01 | 13.01 | 13.29 |
| Quick ratio | 5.48 | 9.52 | 8.93 | 9.49 | 9.99 | 8.63 | 9.74 | 10.50 | 12.42 | 12.65 |
| Cash ratio | 4.68 | 8.34 | 7.81 | 8.50 | 8.97 | 7.78 | 8.59 | 8.89 | 10.89 | 11.27 |
| Leverage | ||||||||||
| Debt / Equity | 0.68 | 0.63 | 0.62 | 0.57 | 0.51 | 0.45 | 0.36 | 0.33 | 0.31 | 0.26 |
| Debt / Assets | 0.33 | 0.35 | 0.34 | 0.33 | 0.31 | 0.28 | 0.24 | 0.23 | 0.22 | 0.19 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -9.8x | - | -6.1x | -9.1x | -11.0x | - | -9.8x | -11.0x | -12.2x | - |
| Equity multiplier | 2.04 | 1.80 | 1.81 | 1.74 | 1.67 | 1.63 | 1.51 | 1.47 | 1.42 | 1.39 |
| Liabilities / Assets | 0.51 | 0.45 | 0.45 | 0.43 | 0.40 | 0.39 | 0.34 | 0.32 | 0.30 | 0.28 |
| Efficiency | ||||||||||
| Asset turnover | 0.18 | - | 0.17 | 0.16 | 0.14 | - | 0.14 | 0.14 | 0.12 | - |
| Inventory turnover | 0.39 | - | 0.34 | 0.48 | 0.42 | - | 0.53 | 0.45 | 0.41 | - |
| Days sales outstanding | 196d | - | 179d | 179d | 196d | - | 234d | 340d | 296d | - |
| Days inventory outstanding | 940d | - | 1076d | 762d | 878d | - | 684d | 818d | 898d | - |
| Days payable outstanding | 199d | - | 235d | 255d | 418d | - | 146d | 232d | 218d | - |
| Cash conversion cycle | 937d | - | 1020d | 687d | 656d | - | 773d | 926d | 977d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 3.8x | - | 2.8x | 3.1x | 1.6x | - | 3.3x | 3.3x | 2.4x | - |
| P / S | 10.3x | - | 9.1x | 10.9x | 7.0x | - | 15.7x | 15.6x | 13.6x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 12.5% | - | -1.2% | -8.5% | -9.1% | - | 0.7% | -9.0% | 2.3% | - |
| Revenue CAGR (3y) | 1.5% | - | 2.1% | 4.3% | 26.6% | - | 32.6% | 19.5% | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 12.5% | - | 1.7% | -9.6% | -8.4% | - | -2.5% | -8.7% | 4.4% | - |
| Operating income growth (YoY) | 10.4% | - | 29.6% | 7.8% | 5.9% | - | 16.3% | 16.7% | 16.2% | - |
| Net income growth (YoY) | 8.3% | - | 26.2% | 3.1% | 13.0% | - | 15.1% | 16.4% | 4.7% | - |
| EPS growth (YoY) | 14.3% | - | 27.3% | 8.0% | 15.2% | - | 18.5% | 50.0% | 5.7% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 38.9% | - | - | - | -17.2% | - | - | - | 43.4% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -30.6% | -26.9% | -32.3% | -31.1% | -28.9% | -27.2% | -25.3% | -25.3% | -25.4% | -24.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$77.36M totalSurgical Glaucoma$75.72M · 97.9%
Dry Eye$1.64M · 2.1%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing Sight Sciences against the 5 most active filers in the same SIC group.